NI
OCRX

Numeric Investors’s Ocera Therapeutics, Inc. OCRX Stock Holding History

Numeric Investors’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-18,600
Closed -$59K – 1213
2015
Q3 		$59K Buy
+18,600
New +$71.6K ﹤0.01% 962

Other funds holding OCRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Numeric Investors's OCRX Position: Q4 2015 in Review

Numeric Investors sold out of Ocera Therapeutics, Inc. (OCRX) in Q4 2015, closing a stake of 18,600 shares — an estimated $59K sold.

Numeric Investors first reported a position in OCRX in Q3 2015 and held it in 1 quarter. The position peaked at $59K in Q3 2015. 29 funds tracked by Wall St. Rank hold OCRX as of Q4 2015.

  • Numeric Investors reported no remaining Ocera Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Numeric Investors sold 18,600 Ocera Therapeutics, Inc. shares in Q4 2015, an estimated $59K.
  • Numeric Investors first reported a position in Ocera Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Numeric Investors's Ocera Therapeutics, Inc. position peaked at $59K in Q3 2015.
  • 29 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q4 2015.

Based on Numeric Investors's 13F filing for Q4 2015, filed 1 Feb 2016.